Jinhyun Cho Selected Research

Thymic epithelial tumor

1/2020	Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment.
1/2019	Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jinhyun Cho Research Topics

Disease

8	Neoplasms (Cancer) 02/2023 - 10/2016
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2018
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 05/2024 - 07/2023
2	Thymic epithelial tumor 01/2020 - 01/2019
2	Melanoma (Melanoma, Malignant) 12/2016 - 12/2016
1	B-Cell Lymphoma (Lymphoma, B Cell) 05/2024
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 11/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020
1	Pericardial Effusion 01/2020
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2019
1	Breast Neoplasms (Breast Cancer) 04/2019
1	Disease Progression 04/2019
1	Cardiotoxicity 04/2019
1	Myoclonus (Nocturnal Myoclonus) 01/2019
1	Thymoma (Thymic Carcinoma) 01/2019
1	Thyroiditis 01/2019
1	Hepatitis 01/2019
1	Glomerulonephritis 01/2019
1	Colitis 01/2019
1	Myasthenia Gravis 01/2019
1	Myocarditis (Carditis) 01/2019
1	Lymphoma (Lymphomas) 08/2018
1	Hypersensitivity (Allergy) 01/2018
1	Thrombocytopenia (Thrombopenia) 01/2018
1	Carcinogenesis 10/2016
1	Tuberous Sclerosis (Bourneville's Disease) 10/2016
1	Hepatocellular Carcinoma (Hepatoma) 10/2016

Drug/Important Bio-Agent (IBA)

4	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2016
4	pembrolizumabIBA 01/2020 - 12/2016
3	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2016
3	NivolumabIBA 01/2020 - 12/2016
2	Chimeric Antigen ReceptorsIBA 05/2024 - 07/2023
2	palbociclibIBA 02/2023 - 11/2020
2	PlatinumIBA 02/2023 - 01/2019
2	Tyrosine Kinase InhibitorsIBA 12/2019 - 04/2019
2	ErbB Receptors (EGF Receptor)IBA 04/2019 - 04/2019
1	Bispecific AntibodiesIBA 05/2024
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2020
1	Cyclin D1IBA 11/2020
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2020
1	Decitabine FDA Link 01/2020
1	Cisplatin (Platino)FDA LinkGeneric 04/2019
1	Trastuzumab (Herceptin)FDA Link 04/2019
1	Pemetrexed (MTA)FDA Link 04/2019
1	Programmed Cell Death 1 ReceptorIBA 01/2019
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 08/2018
1	Indicators and Reagents (Reagents)IBA 01/2018
1	Contrast MediaIBA 01/2018
1	AntibodiesIBA 12/2016
1	VemurafenibIBA 12/2016
1	dabrafenibIBA 12/2016
1	Sorafenib (BAY 43-9006)FDA Link 10/2016
1	Sirolimus (Rapamycin)FDA Link 10/2016
1	MTOR InhibitorsIBA 10/2016

Therapy/Procedure

5	Therapeutics 05/2024 - 01/2019
2	Aftercare (After-Treatment) 12/2020 - 01/2019
1	Salvage Therapy 07/2023
1	Combination Drug Therapy (Combination Chemotherapy) 02/2023
1	Catheters 01/2020
1	Drug Therapy (Chemotherapy) 01/2019